Oral Janus Kinase Inhibitors in Pediatric Vitiligo

Supplementary Figure 1 (Figure 2) shows the percentage of improvement in facial VASI scores over treatment time for all patients. Supplementary Figure 2 (Figure 3) shows the percentage of improvement in trunk VASI scores over treatment time for all patients. Supplementary Table 1 shows the treatment duration for disease progression control in different types of patients. Supplementary Table 2 shows the adverse reactions of the patients.